Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2022 | 162 | 4.490 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 136 | 4.000 |
Why?
|
| Parotid Neoplasms | 3 | 2021 | 14 | 2.090 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 19 | 1.980 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 18 | 1.960 |
Why?
|
| Laryngeal Neoplasms | 5 | 2023 | 28 | 1.900 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 21 | 1.730 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 134 | 1.270 |
Why?
|
| Neck Dissection | 3 | 2021 | 18 | 1.210 |
Why?
|
| Retrospective Studies | 23 | 2023 | 3156 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 183 | 1.090 |
Why?
|
| Facial Nerve | 3 | 2021 | 10 | 1.040 |
Why?
|
| Parotid Gland | 3 | 2021 | 17 | 1.040 |
Why?
|
| Dissection | 3 | 2021 | 24 | 1.040 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 84 | 0.990 |
Why?
|
| Salvage Therapy | 3 | 2023 | 31 | 0.940 |
Why?
|
| Postoperative Complications | 5 | 2020 | 864 | 0.880 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 19 | 0.880 |
Why?
|
| Humans | 38 | 2023 | 24703 | 0.870 |
Why?
|
| Drug Utilization | 2 | 2020 | 20 | 0.830 |
Why?
|
| Narcotics | 2 | 2020 | 34 | 0.810 |
Why?
|
| Analgesia | 2 | 2020 | 36 | 0.800 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.770 |
Why?
|
| Survival Rate | 8 | 2021 | 285 | 0.760 |
Why?
|
| Male | 25 | 2023 | 13669 | 0.750 |
Why?
|
| Middle Aged | 20 | 2021 | 8294 | 0.730 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.700 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 8 | 0.700 |
Why?
|
| Aged | 19 | 2023 | 8382 | 0.700 |
Why?
|
| Surgical Instruments | 1 | 2021 | 20 | 0.700 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.690 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.690 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 29 | 0.690 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.680 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 22 | 0.680 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 41 | 0.680 |
Why?
|
| Prescriptions | 1 | 2020 | 16 | 0.670 |
Why?
|
| Female | 22 | 2021 | 14048 | 0.660 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 55 | 0.650 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 305 | 0.640 |
Why?
|
| Sarcoma | 1 | 2021 | 71 | 0.640 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.630 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2019 | 3 | 0.620 |
Why?
|
| Pharyngectomy | 1 | 2019 | 3 | 0.620 |
Why?
|
| Recovery of Function | 1 | 2020 | 292 | 0.620 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 61 | 0.610 |
Why?
|
| Databases, Factual | 4 | 2021 | 315 | 0.490 |
Why?
|
| Adult | 13 | 2020 | 7255 | 0.460 |
Why?
|
| Tonsillar Neoplasms | 1 | 2014 | 3 | 0.440 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 14 | 0.430 |
Why?
|
| Laryngectomy | 4 | 2023 | 16 | 0.430 |
Why?
|
| Dura Mater | 1 | 2014 | 18 | 0.430 |
Why?
|
| Teratoma | 1 | 2012 | 3 | 0.400 |
Why?
|
| Surgical Flaps | 1 | 2012 | 48 | 0.380 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.370 |
Why?
|
| Angioedema | 1 | 2011 | 2 | 0.370 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 14 | 0.370 |
Why?
|
| Airway Obstruction | 1 | 2011 | 18 | 0.370 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 332 | 0.370 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.360 |
Why?
|
| Ear Diseases | 1 | 2011 | 2 | 0.360 |
Why?
|
| Nose Diseases | 1 | 2011 | 6 | 0.360 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 35 | 0.350 |
Why?
|
| Hypersensitivity | 1 | 2011 | 37 | 0.350 |
Why?
|
| Gravitation | 1 | 2010 | 1 | 0.350 |
Why?
|
| Ear Canal | 1 | 2010 | 2 | 0.350 |
Why?
|
| Barotrauma | 1 | 2010 | 3 | 0.350 |
Why?
|
| Tympanic Membrane | 1 | 2010 | 2 | 0.350 |
Why?
|
| Accidents | 1 | 2010 | 2 | 0.350 |
Why?
|
| Head Movements | 1 | 2010 | 6 | 0.350 |
Why?
|
| Leisure Activities | 1 | 2010 | 15 | 0.350 |
Why?
|
| Prognosis | 3 | 2019 | 674 | 0.350 |
Why?
|
| Tongue | 2 | 2021 | 8 | 0.350 |
Why?
|
| Acceleration | 1 | 2010 | 20 | 0.350 |
Why?
|
| Edema | 1 | 2010 | 25 | 0.340 |
Why?
|
| United States | 6 | 2021 | 1873 | 0.340 |
Why?
|
| Chylothorax | 1 | 2010 | 1 | 0.330 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 303 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 85 | 0.320 |
Why?
|
| Cohort Studies | 4 | 2020 | 1748 | 0.320 |
Why?
|
| Papillomaviridae | 2 | 2022 | 17 | 0.310 |
Why?
|
| Young Adult | 6 | 2020 | 1847 | 0.310 |
Why?
|
| Betacoronavirus | 2 | 2020 | 62 | 0.310 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 145 | 0.300 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 75 | 0.300 |
Why?
|
| Lens Cortex, Crystalline | 1 | 2007 | 3 | 0.290 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2007 | 6 | 0.280 |
Why?
|
| Lens, Crystalline | 1 | 2007 | 33 | 0.280 |
Why?
|
| Adolescent | 4 | 2020 | 1992 | 0.270 |
Why?
|
| Risk Assessment | 2 | 2019 | 532 | 0.270 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3208 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 29 | 0.260 |
Why?
|
| Margins of Excision | 2 | 2021 | 24 | 0.220 |
Why?
|
| Neck | 2 | 2023 | 23 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 32 | 0.210 |
Why?
|
| Otolaryngology | 2 | 2020 | 24 | 0.210 |
Why?
|
| Pilot Projects | 2 | 2022 | 370 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4509 | 0.200 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 12 | 0.200 |
Why?
|
| SEER Program | 2 | 2019 | 36 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2021 | 1612 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.190 |
Why?
|
| Age Factors | 3 | 2019 | 728 | 0.190 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 278 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 57 | 0.190 |
Why?
|
| Length of Stay | 2 | 2023 | 294 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 41 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2020 | 467 | 0.180 |
Why?
|
| Risk Factors | 3 | 2021 | 2099 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 25 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2019 | 3 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 118 | 0.160 |
Why?
|
| Frailty | 1 | 2019 | 28 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 88 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 8 | 0.160 |
Why?
|
| Head | 1 | 2019 | 16 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 138 | 0.160 |
Why?
|
| Medical Illustration | 1 | 2019 | 13 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2019 | 69 | 0.160 |
Why?
|
| Larynx | 1 | 2019 | 10 | 0.150 |
Why?
|
| Pharynx | 1 | 2019 | 11 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 41 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 44 | 0.150 |
Why?
|
| Reference Values | 1 | 2019 | 174 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 74 | 0.150 |
Why?
|
| Morphine | 1 | 2019 | 71 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1671 | 0.150 |
Why?
|
| Aging | 1 | 2007 | 1460 | 0.150 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 304 | 0.150 |
Why?
|
| Carcinoma | 1 | 2018 | 65 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 437 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.130 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 222 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 21 | 0.120 |
Why?
|
| Markov Chains | 1 | 2015 | 31 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 45 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 118 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 93 | 0.120 |
Why?
|
| Rhinitis | 1 | 2017 | 135 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 151 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 49 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 95 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 348 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 315 | 0.100 |
Why?
|
| Drainage | 2 | 2010 | 41 | 0.100 |
Why?
|
| Cricoid Cartilage | 1 | 2012 | 1 | 0.100 |
Why?
|
| Forearm | 1 | 2012 | 18 | 0.100 |
Why?
|
| Mouth Floor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tongue Diseases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Trachea | 1 | 2012 | 38 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2012 | 32 | 0.090 |
Why?
|
| Laryngoscopy | 1 | 2011 | 18 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 21 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 64 | 0.090 |
Why?
|
| Otoscopy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hearing Tests | 1 | 2010 | 11 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 87 | 0.080 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 3 | 0.080 |
Why?
|
| Hematoma | 1 | 2010 | 16 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 246 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 330 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 281 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 245 | 0.070 |
Why?
|
| Pandemics | 2 | 2020 | 190 | 0.070 |
Why?
|
| Hypertension | 1 | 2010 | 169 | 0.070 |
Why?
|
| Lasers | 1 | 2007 | 13 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 23 | 0.070 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 33 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 73 | 0.070 |
Why?
|
| Fetus | 1 | 2007 | 34 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 178 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 613 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 12 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 48 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 6 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 197 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 231 | 0.040 |
Why?
|
| Animals | 1 | 2007 | 3330 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 29 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 53 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 279 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 63 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 165 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 443 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 858 | 0.030 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.030 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.030 |
Why?
|
| Nasal Surgical Procedures | 1 | 2017 | 10 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 39 | 0.030 |
Why?
|
| Nose | 1 | 2017 | 32 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 160 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 168 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 211 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 145 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 176 | 0.030 |
Why?
|